Evidence map›Paper›PMID 36341449›Full record

ArticleFrontiers in immunology2022

Archetypal type II and III

Andrea Largo-de la Torre, Carlos Diezma-Díaz, Rafael Calero-Bernal, Gabriela Atencia-Cibreiro, Roberto Sánchez-Sánchez, Ignacio Ferre, Javier Regidor-Cerrillo, Luis Miguel Ortega-Mora

Open access · goldAbstract readRandomized Controlled Trial, Veterinary
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Treatment with BKI-1748 afterAntimicrobial agents and chemotherapy · 2025
    Article
  8. Article
  9. Limited value of current and newFrontiers in parasitology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Andrea Largo-de la TorreSALUVET-Innova, Faculty of Veterinary Sciences, Complutense University of Madrid, Madrid, Spain.
Carlos Diezma-DíazSALUVET-Innova, Faculty of Veterinary Sciences, Complutense University of Madrid, Madrid, Spain.
Rafael Calero-BernalSALUVET, Animal Health Department, Faculty of Veterinary Sciences, Complutense University of Madrid, Madrid, Spain.
Gabriela Atencia-CibreiroSALUVET-Innova, Faculty of Veterinary Sciences, Complutense University of Madrid, Madrid, Spain.
Roberto Sánchez-SánchezSALUVET, Animal Health Department, Faculty of Veterinary Sciences, Complutense University of Madrid, Madrid, Spain.
Ignacio FerreSALUVET-Innova, Faculty of Veterinary Sciences, Complutense University of Madrid, Madrid, Spain.
Javier Regidor-CerrilloSALUVET-Innova, Faculty of Veterinary Sciences, Complutense University of Madrid, Madrid, Spain.
Luis Miguel Ortega-MoraSALUVET-Innova, Faculty of Veterinary Sciences, Complutense University of Madrid, Madrid, Spain.
Universidad Complutense de Madrid · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Livestock animals, such as swine, are an important source of

Indexed as

ToxoplasmaToxoplasmosis, AnimalAnimalsFemaleImmunityImmunoglobulin GInterleukin-12Interleukin-8OocystsSwineImmunoglobulin GInterleukin-12Interleukin-8clinical outcomeimmune responseoocystsparasite disseminationpigletsToxoplasma gondiitype II and type III isolates

Identifiers

PMID36341449
PMCPMC9631316
OpenAlexW4306943866

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.